MRD-Guided Immunotherapy for Lung Cancer After Chemo and Radiation
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests an immunotherapy (PD-L1 inhibitor) for people with limited-stage small cell lung cancer whose cancer stayed stable after chemo and radiation but still has MRD (small traces of cancer in the blood). The goal is to see if this treatment can help prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 79 years old
- You have limited-stage small cell lung cancer that did not get worse after chemo and radiation
- You have never had immunotherapy (like a PD-L1 inhibitor) before
- After chemo and radiation, a blood test found MRD (cancer DNA fragments)
- You have no other active cancer, severe heart problems, or uncontrolled bleeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding the immunotherapy drug adebrelimab to standard chemotherapy and radiation to see if it works better than chemotherapy alone for people newly diagnosed with extensive-stage small cell lung cancer.
This trial tests a new immunotherapy drug called adebrelimab combined with standard chemotherapy and radiation for people with limited-stage small cell lung cancer. After the initial treatment, adebrelimab is continued alone to help prevent the cancer from coming back.
This study tests a new immunotherapy drug called adebrelimab combined with standard chemotherapy and radiation treatment for patients with advanced non-small cell lung cancer that cannot be surgically removed. The goal is to improve how well treatment works and help patients live longer.
This trial tests a drug called Adebrelimab as a maintenance therapy after you finish chemotherapy and radiation (given in smaller, more frequent doses) for limited-stage small cell lung cancer. The goal is to see if it helps keep the cancer from coming back.
This trial tests whether adding a cancer-fighting immunotherapy (tislelizumab) and chemotherapy after surgery can lower the chance of lung cancer coming back. It uses “MRD” (measurable remaining disease) to help decide who may benefit the most after resection.
This trial tests whether adding two drugs (adebrelimab and apatinib) after standard chemoradiation can help prevent cancer from coming back in people with limited-stage small cell lung cancer. It is for patients whose cancer did not grow after chemoradiation.
Hear when a new Small Cell Lung Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.